Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Galimberti, Sara ^a   Guerrini, Francesca ^a   Salvi, Flavia ^b   Petrini, Iacopo ^a   Gioia, Daniela ^b   Messa, Emanuela ^b   Palumbo, Giuseppe A ^c   Cilloni, Daniela ^d   Petrini, Mario ^a   Levis, Alessandro ^b  

^a UNIVERSITY OF PISA   (Italy)

^b C Arrigo Children's Hospital   (Italy)

^c Section of Hematology Oncology and General Pathology   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Apoptosis; Ascorbic acid; ATO; MDS; Myelodysplastic syndromes

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BCL 2 LIKE 10 PROTEIN; BCL 2 LIKE 14 PROTEIN; BETA ACTIN; CASPASE 14; CASPASE 5; EVI1 PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ICEBERG PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; PROTEIN HRK; RNA 18S; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPER FAMILY MEMBER 1A; UNCLASSIFIED DRUG; WT1 PROTEIN;

AGED; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CLINICAL ARTICLE; DOWN REGULATION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOUSEKEEPING GENE; HUMAN; MALE; MULTIGENE FAMILY; MYELODYSPLASTIC SYNDROME; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

AGED; APOPTOSIS; ARSENICALS; ASCORBIC ACID; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; OXIDES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84865854047     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-53     Document Type: Article

References (22)

1. Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. Ho SY, Wu WJ, Chiu HW, Chen YA, Ho YS, Guo HR, Wang YJ, Chem Biol Interact 2011 193 162 167 10.1016/j.cbi.2011.06.007 21741957
2. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF, J Clin Oncol 2006 24 2456 2464 10.1200/JCO.2005.03.7903 16651647 (Pubitemid 46630622)
3. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P, J Clin Oncol 2006 24 2465 2471 10.1200/JCO.2005.03.9503 16651646 (Pubitemid 46630623)
4. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF, Leuk Res 2008 32 251 254 10.1016/j.leukres.2007.05.025 17920679 (Pubitemid 351215536)
5. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Perkins C, Kim CN, Fang G, Bhalla KN, Blood 2000 95 1014 1022 10648417 (Pubitemid 30062726)
6. Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Scholz C, Richter A, Lehmann M, Schulze-Osthoff K, Dorken B, Daniel PT, Oncogene 2005 24 7031 7042 10.1038/sj.onc.1208868 16007134 (Pubitemid 41573632)
7. Inhibition of NF-kappa B essentially contributes to arsenic-induced apoptosis. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B, Blood 2003 102 1028 1034 10.1182/blood-2002-04-1154 12676792 (Pubitemid 36917800)
8. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. Yedjou C, Tchounwou P, Jenkins J, McMurray R, J Hematol Oncol 2010 23 28
9. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Huang XJ, Wiernik PH, Klein RS, Gallagher RE, Med Oncol 1999 16 58 64 10.1007/BF02787360 10382944 (Pubitemid 29238383)
10. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S, Blood 2000 96 1525 1530 10942401 (Pubitemid 30658486)
11. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N, Metelli MR, Petrini M, Cancer Genet Cytogenet 2010 199 110 120 10.1016/j.cancergencyto.2010.02.010 20471514
12. WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Galimberti S, Ghio F, Guerrini F, Ciabatti E, Grassi S, Ferreri MI, Petrini M, Br J Haematol 2010 149 451 454 10.1111/j.1365-2141. 2009.08063.x 20085581
13. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R, Cancer Res 2006 66 11360 11369 10.1158/0008-5472.CAN-06-1774 17145882 (Pubitemid 46009967)
14. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M, J Clin Oncol 2007 25 3503 3510 10.1200/JCO.2006.08.5696 17687155 (Pubitemid 47315575)
15. Prognostic factors and scoring systems in myelodysplastic syndromes. Sanz GF, Sanz MA, Greenberg PL, Haematologica 1998 83 358 368 9592987 (Pubitemid 28217858)
16. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H, Blood 2006 108 419 425 10.1182/blood-2005-10-4149 16609072 (Pubitemid 44061337)
17. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Boudard D, Sordet O, Vasselon C, Revol V, Berthéas MF, Freyssenet D, Viallet A, Piselli S, Guyotat D, Campos L, Leukemia 2000 14 2045 2051 10.1038/sj.leu.2401959 11187891 (Pubitemid 32042241)
18. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, Kambhampati S, Leuk Lymphoma 2008 49 1963 1975 10.1080/10428190802322919 18949619
19. Molecular cloning and expression of a receptor for human tumor necrosis factor. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H, Cell 1990 61 361 370 10.1016/0092-8674(90)90816-W 2158863 (Pubitemid 120035001)
20. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Nolte F, Hofmann WK, Future Oncol 2010 6 445 455 10.2217/fon.09.175 20222800
21. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C, Blood 2009 113 6541 6548 10.1182/blood-2009-02-202598 19389880
22. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW, Cancer Res 2008 68 3421 3428 10.1158/0008-5472.CAN-07- 5836 18451170